1 of 1
Story summary
- National Institute for Health and Care Excellence approved Opzelura (ruxolitinib) cream for vitiligo in patients aged 12 and older after other treatments fail.
- The National Health Service will soon provide Opzelura to eligible patients.
- Clinical trials showed significant pigmentation improvement for about one-third of users.
- Gill from Lancashire expresses frustration over vitiligo's impact on daily life.
